Relief

Relief Mental Health Honors Psychiatric Physician Assistant Jamie Pacilio as Provider of the Month

Retrieved on: 
Tuesday, January 30, 2024
Hospitals, Pharmaceutical, Health, Mental Health, Anxiety, Provider, Mental health, Relief, Patient, Transcranial magnetic stimulation, MSPAS, FDA, OCD, Ketamine, TMS, Depression, Specialization, Month, Mental, Nursing

Relief Mental Health is proud to announce Jamie Pacilio, MSPAS, PA-C , psychiatric physician assistant in its Red Bank clinic , as the recipient of its prestigious Provider of the Month award.

Key Points: 
  • Relief Mental Health is proud to announce Jamie Pacilio, MSPAS, PA-C , psychiatric physician assistant in its Red Bank clinic , as the recipient of its prestigious Provider of the Month award.
  • As a highly skilled psychiatric medical provider, Pacilio has been an integral part of Relief’s mission in New Jersey to deliver comprehensive and personalized mental health services.
  • One of the distinctive offerings at Relief Mental Health is transcranial magnetic stimulation (TMS) therapy, and Pacilio has played a key role in the success of this initiative.
  • Relief congratulates Pacilio on this well-deserved honor and expresses gratitude for her continued contributions to the field of mental health.

Jewelers Mutual® Expands Counseling Benefit Globally

Retrieved on: 
Wednesday, November 8, 2023
Hand, Insurance, Face, United Kingdom, Health, Relief

NEENAH, Wis., Nov. 8, 2023 /PRNewswire/ -- Jewelers Mutual® Group, the insurance and business solutions provider dedicated to the jewelry industry since 1913, recently announced the expansion of its "Relieve" counseling service in response to heartbreak being felt in the US and across the world. This service, a complimentary benefit for its commercially insured customers, has been extended to the entire jewelry industry through December 31, 2023, free of charge. The insurer has secured professional telephone counseling services across five countries with potential for further expansion.

Key Points: 
  • This service, a complimentary benefit for its commercially insured customers, has been extended to the entire jewelry industry through December 31, 2023, free of charge.
  • The insurer has secured professional telephone counseling services across five countries with potential for further expansion.
  • Jewelers Mutual offers the Relieve benefit, through TELUS® Health, which provides counseling services with qualified professional counselors at no charge for jewelers, their direct families and employees who may need support, guidance and healing.
  • Key features of the Relieve counseling service:
    The extension of the Relieve counseling service underscores Jewelers Mutual's dedication to the wellbeing and vitality of its valued customers and the jewelry industry.

Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Friday, September 1, 2023
Relief Therapeutics, OTCQB, Lotte New York Palace Hotel, Madison Avenue, Rare, Therapy, Conference, 50th Street, Pharmaceutical industry, Hotel, Relief

Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Key Points: 
  • Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
    Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
    GENEVA (SEPT. 1, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that Jack Weinstein, chief executive officer, will present a company overview during the H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 at the Lotte New York Palace hotel in New York.
  • Location: Lotte New York Palace Hotel, 455 Madison Avenue at 50th Street, New York, NY 10022
    Management will host one-on-one meetings during the event.
  • Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company.
  • A live webcast of the Relief Therapeutics presentation can be found at the following link: https://journey.ct.events/view/6db5b681-f490-4229-8384-6ac135554cfc and will be archived for a period of 90 days after the conference.

Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe

Retrieved on: 
Wednesday, August 30, 2023
Heart, Principality, Maple syrup urine disease, Fatigue, BSA, Diet, Relief Therapeutics, CLA, Edema, UCD, Probenecid, Appetite, Valproate, Vomiting, Patient Information Advisory Group, Relief, UCD School of Medicine, Acquisition, Metabolism, Patient, Ammonia, Swelling, CPS, Blood, Child, Hypokalemia, European, ELA, OTC, Somnolence, ACER, Nausea, Confusion, Liver, FDA, Therapy, Lightheadedness, Headache, Potassium, Sodium, Neurotoxicity, Haloperidol, Pharmaceutical industry, Maple syrup, Acer

OLPRUVA™ is approved in the U.S. for the treatment of certain urea cycle disorders (UCDs).

Key Points: 
  • OLPRUVA™ is approved in the U.S. for the treatment of certain urea cycle disorders (UCDs).
  • Acer and Relief have now agreed to terminate the CLA, where Acer is no longer required to pay Relief 60% of OLPRUVA™ net profits in the Acer territories and have regained all development and commercialization rights in rest of the world, excluding the Geographical Europe.
  • Additionally, Acer and Relief have entered into a new Exclusive License Agreement (ELA) in which Relief will retain development and commercialization rights for OLPRUVA™ in the Geographical Europe, where Acer will have the right to receive a royalty of up to 10% of the net sales of OLPRUVA™.
  • For additional Important Safety Information, see full Prescribing Information , Patient Package Insert and discuss with your doctor.

Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health

Retrieved on: 
Wednesday, July 19, 2023
Partnership, Relief Therapeutics, Phenylketonuria, Taste, Health, OTCQB, Malnutrition, PKU, Phenylalanine, Acquisition, Patient, Distribution, Rare, Therapy, Pharmaceutical industry, Medicaid, Relief

This enables Relief Therapeutics to broaden distribution of PKU GOLIKE® across an expanded commercial payor base, ensuring more patients living with PKU will have access to the PKU GOLIKE® family of products to help them manage their condition.

Key Points: 
  • This enables Relief Therapeutics to broaden distribution of PKU GOLIKE® across an expanded commercial payor base, ensuring more patients living with PKU will have access to the PKU GOLIKE® family of products to help them manage their condition.
  • “Working together, Pentec Health, ZOIA Pharma and Relief Therapeutics are helping to solve problems in the rare disease world to improve the health of people with these conditions,” said Matthew Deans, president and chief executive officer of Pentec Health.
  • “The combined forces of Pentec Health and Zoia Pharma is one of the most consequential developments in the past decade for the distribution of medical foods,” said Chris Wick, U.S. country lead of Relief Therapeutics.
  • “The expanded reach and capabilities will enable us to serve more patients in the PKU community with PKU GOLIKE® for years to come.”

E4E Relief launches first-of-its-kind Emergency Financial Relief℠ platform

Retrieved on: 
Wednesday, June 7, 2023
Workforce, Social impact, Wildfire, COVID-19, Intelligence, Microsoft, Emergency, Research, History, Confidentiality, Relief, Disaster, Flood, Investment, KPMG, Video game, Risk management, Pharmaceutical industry

The Emergency Financial Relief platform now makes financial relief and its corresponding business and social impact available to all stakeholders material to the success of a business, including employees and contractors, as well as franchisees, suppliers, vendors, customers and the broader community.

Key Points: 
  • The Emergency Financial Relief platform now makes financial relief and its corresponding business and social impact available to all stakeholders material to the success of a business, including employees and contractors, as well as franchisees, suppliers, vendors, customers and the broader community.
  • E4E Relief recently embarked on an unprecedented effort to understand the business and social outcomes of emergency financial relief among grant recipients.
  • The result of this effort is the launch of ImpactStack℠, E4E Relief’s multifaceted approach to measuring the impact of emergency financial relief.
  • “Our data and proprietary framework demonstrate that emergency financial relief improves financial stability, which increases productivity, engagement and loyalty for the companies funding these programs.

Emergency Financial Relief Organization Selects Tipalti to Accelerate Payment Processes to People Affected by Global Disasters and Hardships

Retrieved on: 
Wednesday, May 24, 2023
Partnership, Disaster, Averting Loss of Life and Injury by Expediting SIVs Act of 2021, Relief, Child, Digital economy, Pembrokeshire Action To Combat Hardship, Cryptocurrency, Life insurance, Tipalti

FOSTER CITY, Calif., May 24, 2023 /PRNewswire/ -- Tipalti, the leading global payables automation solution, announced that charitable emergency financial relief provider E4E Relief has joined its customer base. E4E Relief selected Tipalti to help the organization support the well-being of individuals worldwide by expediting the distribution of much-needed funds during some of the hardest times of people's lives. Founded in 2001, E4E Relief offers a unique workforce solution to companies, allowing them to put their people first by delivering grants quickly and efficiently to support employees and other stakeholders during times of disaster or hardship. Serving more than 50 Fortune 500 companies, E4E Relief has distributed grants totaling more than $220 million in the past three years alone. 

Key Points: 
  • Tipalti helps financial first responder E4E Relief deliver financial support globally, including awarding more than $60M during 2022 in days instead of weeks
    FOSTER CITY, Calif., May 24, 2023 /PRNewswire/ -- Tipalti , the leading global payables automation solution, announced that charitable emergency financial relief provider E4E Relief has joined its customer base.
  • Serving more than 50 Fortune 500 companies, E4E Relief has distributed grants totaling more than $220 million in the past three years alone.
  • In 2021, E4E Relief selected Tipalti as one of its global payments partners to scale its work internationally and continue providing relief to those in need with optimum security and efficiency.
  • With Tipalti, E4E Relief can now diversify its payment options and increase the speed of disbursement in all currencies, a capability that was crucial in the organization's 2022 Ukraine relief efforts.

Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory

Retrieved on: 
Monday, May 15, 2023
GMP, Good manufacturing practice, Relief Therapeutics, International Council, OTCQB, Viscometer, ICH, Research, Australia New Zealand Therapeutic Products Authority, Relief, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Documentation, CGMP, Patient, Agency, Rare, Harmonization, APR, Therapy, HPLC, Fine chemical, Pharmaceutical industry

Swissmedic is the national authorization and supervisory authority for drugs and medical products and devices.

Key Points: 
  • Swissmedic is the national authorization and supervisory authority for drugs and medical products and devices.
  • The next-generation laboratory in Balerna, Switzerland is run by Relief Therapeutics’ subsidiary APR Applied Pharma Research SA (APR) and offers a comprehensive suite of analytical and development services for internal projects and provides external clients with data and full documentation to meet current Good Manufacturing Practice (cGMP), International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) and international regulatory authority requirements.
  • “GMP compliance is a critical achievement for our laboratory, enabling us to create, safeguard and supply high-quality products to patients and healthcare providers as well as enable the future submissions of product files to regulatory authorities,” said Paolo Galfetti, chief operating officer of Relief Therapeutics and chief executive officer of APR.
  • “We are excited that our new GMP-compliant lab in Balerna, where innovation is driven by our experienced and highly talented employees, is now Swissmedic-approved and operational,” said Jack Weinstein, chief executive officer of Relief Therapeutics.

Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares

Retrieved on: 
Wednesday, May 3, 2023
SIX Swiss Exchange, Relief, OTCQB, Rare, Relief Therapeutics, Therapy, Extraordinary general meeting, Pharmaceutical industry, Security (finance), Fine chemical

GENEVA (May 3, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced the implementation timeline for the reverse split of its ordinary shares, which was approved by shareholders at the Extraordinary General Meeting held on April 28, 2023.

Key Points: 
  • GENEVA (May 3, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced the implementation timeline for the reverse split of its ordinary shares, which was approved by shareholders at the Extraordinary General Meeting held on April 28, 2023.
  • As previously communicated, shareholdings will be rounded down to the next lower whole number of new merged shares by applying the 400 to 1 exchange ratio.
  • The resulting fractions will be compensated in cash at a fixed price corresponding to the three-day volume-weighted average price of the Relief Therapeutics share on the SIX Swiss Exchange prior to the reverse split.

Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

Retrieved on: 
Monday, May 1, 2023
SIX Swiss Exchange, Relief Therapeutics, ADR, Q&A, 1:200 scale, OTCQB, EGM, ADR Institute of Alberta, Relief, VWAP, Rare, Therapy, Proxy, Security (finance), Pharmaceutical industry, Management

The share consolidation is an important step to bringing us closer to our goal of listing on the Nasdaq,” said Jack Weinstein, chief executive officer of Relief Therapeutics.

Key Points: 
  • The share consolidation is an important step to bringing us closer to our goal of listing on the Nasdaq,” said Jack Weinstein, chief executive officer of Relief Therapeutics.
  • There can be no assurance that Nasdaq will approve the Relief Therapeutics listing application.
  • If Relief Therapeutics' shares are successfully listed on Nasdaq, the ADRs will be exchanged against ordinary registered shares.
  • The voting results of the EGM are available on the same page of the Relief Therapeutics website.